Beam Therapeutics Q4 net income $142.8M; cash $1.2B, runway to 2027

Beam Therapeutics Inc.

2023-FY EPS reported -$1.72 revenue$377,709,000

Q4 net income $142.8M ($1.77 basic EPS) vs net loss $38.3M in Q4 2022; full-year net loss $132.5M vs $289.1M loss in 2022.
Cash, equivalents and marketable securities $1.2B at Dec 31, 2023, expected to fund operations into 2027.
BEAM-101 in SCD: sentinel cohort dosing and expansion cohort initiation H1 2024; initial clinical data expected H2 2024.
BEAM-302 for AATD Phase 1 trial initiation on track for H1 2024 pending CTA acceptance; BEAM-301 IND submission H1 2024.
R&D expenses rose to $140.1M Q4 (vs $86.3M) and $437.4M FY (vs $311.6M); G&A expenses $43.3M Q4 (vs $22.7M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beam Therapeutics Inc. reported the year ended December 31, 2023 results: net income net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 202, EPS $1.72 per share.

Period: the year ended December 31, 2023
Net income: net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 202
EPS: $1.72 per share
Result: reported results

Exact text from the filing

net loss attributable to common stockholders was $132.5 million, or $1.72 per share, for the year ended December 31, 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beam Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share,, EPS $1.77 per basic share and $1.73 per diluted share.

Period: the fourth quarter of 2023
Net income: Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share,
EPS: $1.77 per basic share and $1.73 per diluted share
Result: reported results

Exact text from the filing

Net income attributable to common stockholders was $142.8 million, or $1.77 per basic share and $1.73 per diluted share, for the fourth quarter of 2023

View on SEC.gov

Browse all earnings releases →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-020608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.